Paris and Cambridge, MA. June 2, 2025. Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare ...

Sanofi SNY announced that it has entered into a definitive agreement to acquire Blueprint Medicines BPMC for a total deal value of up to $9.5 billion. Following the announcement, shares of BPMC are up ...

LONDON — Moderna may be best known for its Covid-19 vaccine, but since its start, it’s always been set on developing therapies. On Wednesday, scientists reported interim results from an early study of ...

BeOne Medicines (ONC) announced an update on their ongoing clinical study. BeOne Medicines is running an early-stage trial to test a new cancer drug, BG-75098, in adults with advanced solid tumors.

Sanofi has agreed to acquire Blueprint Medicines for up to approximately $9.5 billion, the companies said today, in a deal designed to expand the buyer’s rare immunological disease portfolio with an ...

The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Furthermore, ...